<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01344304</url>
  </required_header>
  <id_info>
    <org_study_id>SENRI</org_study_id>
    <nct_id>NCT01344304</nct_id>
  </id_info>
  <brief_title>Study of Aprepitant / Fosaprepitant for the Prevention of Chemotherapy-induced Nausea and Vomiting (CINV) in Colorectal Cancer Patients - SENRI Trial</brief_title>
  <official_title>Multicenter Randomized Controlled Trial of Combination Antiemetic Therapy With Aprepitant / Fosaprepitant in Patients With Colorectal Cancer Receiving Oxaliplatin-based Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Multicenter Clinical Study Group of Osaka, Colorectal Cancer Treatment Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Multicenter Clinical Study Group of Osaka, Colorectal Cancer Treatment Group</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The object of this study is to evaluate the superiority of aprepitant therapy with a&#xD;
      5HT3-receptor antagonist, dexamethasone and aprepitant compared to standard therapy with a&#xD;
      5HT3-receptor antagonist and dexamethasone for prevention of nausea and vomiting in first&#xD;
      course chemotherapy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2011</start_date>
  <completion_date type="Actual">April 2015</completion_date>
  <primary_completion_date type="Actual">November 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Patient diary recording nausea, emesis, food ingestion, and rescue therapy</measure>
    <time_frame>From initiating administration of anticancer agents to day 6 (120 hours)</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">413</enrollment>
  <condition>Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>Standard therapy</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>The patients are treated with 5HT3-receptor antagonist + dexamethasone during the first course, then treated with aprepitant / fosaprepitant + 5HT3-receptor antagonist + dexamethasone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aprepitant / Fosaprepitant therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The patients are treated with aprepitant / fosaprepitant + 5HT3-receptor antagonist + dexamethasone during first and second courses.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aprepitant / Fosaprepitant</intervention_name>
    <description>Aprepitant:&#xD;
125 mg PO on day 1 80 mg PO on days 2 to 3&#xD;
Fosaprepitant:&#xD;
150 mg IV on day 1</description>
    <arm_group_label>Aprepitant / Fosaprepitant therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age: ≥20 years old&#xD;
&#xD;
          -  Sex: Not specified&#xD;
&#xD;
          -  Patients with colon/rectal cancer who first underwent FOLFOX, XELOX or SOX regimen&#xD;
             including oxaliplatin at ≥85 mg/m2 (naive patient), or those who had already started&#xD;
             chemotherapy and had nausea of Grade 2 or higher in the last course or an earlier&#xD;
             course (non-naive patient).&#xD;
&#xD;
          -  Stage: not specified (neoadjuvant/adjuvant chemotherapy, advanced or recurrent type&#xD;
             are allowed)&#xD;
&#xD;
          -  Combination of molecular targeted therapy: allowable&#xD;
&#xD;
          -  Written informed consent for participation in the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Severe liver or kidney disease&#xD;
&#xD;
          -  Nausea/vomiting within 24 hr prior to chemotherapy.&#xD;
&#xD;
          -  Treatment with antiemetics within 24 hr prior to chemotherapy.&#xD;
&#xD;
          -  Presence of factors causing nausea/vomiting other than chemotherapy (e.g. brain tumor,&#xD;
             gastrointestinal obstruction, active peptic ulcer disease, brain metastasis)&#xD;
&#xD;
          -  Presence of a disease precluding 3-day administration of dexamethasone (e.g.&#xD;
             uncontrollable diabetes)&#xD;
&#xD;
          -  Pregnant or lactating women, women who plan to become pregnant.&#xD;
&#xD;
          -  Current treatment with pimozide.&#xD;
&#xD;
          -  Any patient judged to be inappropriate for the study by the investigator.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Kansai Rosai Hospital</name>
      <address>
        <city>Amagasaki</city>
        <state>Hyogo</state>
        <zip>6600064</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kinki Central Hospital</name>
      <address>
        <city>Itami</city>
        <state>Hyogo</state>
        <zip>6640872</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kawasaki Hospital</name>
      <address>
        <city>Kobe</city>
        <state>Hyogo</state>
        <zip>6520042</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nara Hospital Kinki University Faculty of Medicine</name>
      <address>
        <city>Ikoma</city>
        <state>Nara</state>
        <zip>6300293</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Higashiosaka City General Hospital</name>
      <address>
        <city>Higashi-Osaka</city>
        <state>Osaka</state>
        <zip>5788588</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saito Yukoukai Hospital</name>
      <address>
        <city>Ibaraki</city>
        <state>Osaka</state>
        <zip>5670085</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rinku General Medical Center</name>
      <address>
        <city>Izumisano</city>
        <state>Osaka</state>
        <zip>5988577</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaizuka City Hospital</name>
      <address>
        <city>Kaizuka</city>
        <state>Osaka</state>
        <zip>5970015</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hannan Chuo Hospital</name>
      <address>
        <city>Matsubara</city>
        <state>Osaka</state>
        <zip>5800023</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Minoh City Hospital</name>
      <address>
        <city>Minoo</city>
        <state>Osaka</state>
        <zip>5620014</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sakai City Hospital</name>
      <address>
        <city>Sakai</city>
        <state>Osaka</state>
        <zip>5900064</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osaka Rosai Hospital</name>
      <address>
        <city>Sakai</city>
        <state>Osaka</state>
        <zip>5918025</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Suita Municipal Hospital</name>
      <address>
        <city>Suita</city>
        <state>Osaka</state>
        <zip>5640082</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saiseikai Senri Hospital</name>
      <address>
        <city>Suita</city>
        <state>Osaka</state>
        <zip>5650862</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Graduate School of Medicine / Faculty of Medicine, Osaka University</name>
      <address>
        <city>Suita</city>
        <state>Osaka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toyonaka Municipal Hospital</name>
      <address>
        <city>Toyonaka</city>
        <state>Osaka</state>
        <zip>5608565</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yao Municipal Hospital</name>
      <address>
        <city>Yao</city>
        <state>Osaka</state>
        <zip>5810069</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kenporen Osaka Central Hospital</name>
      <address>
        <city>Osaka</city>
        <zip>5300001</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Iseikai Hospital</name>
      <address>
        <city>Osaka</city>
        <zip>5330022</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osaka Medical Center for Cancer and Cardiovascular Diseases</name>
      <address>
        <city>Osaka</city>
        <zip>5378511</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization Osaka National Hospital</name>
      <address>
        <city>Osaka</city>
        <zip>5400006</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NTT West Osaka Hospital</name>
      <address>
        <city>Osaka</city>
        <zip>5430042</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nissay Hospital</name>
      <address>
        <city>Osaka</city>
        <zip>5500012</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tane General Hospital</name>
      <address>
        <city>Osaka</city>
        <zip>5500024</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osaka Seninhoken Hospital</name>
      <address>
        <city>Osaka</city>
        <zip>5520021</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osaka Koseinenkin Hospital</name>
      <address>
        <city>Osaka</city>
        <zip>5530003</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osaka General Medical Center</name>
      <address>
        <city>Osaka</city>
        <zip>5588558</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>April 27, 2011</study_first_submitted>
  <study_first_submitted_qc>April 28, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 29, 2011</study_first_posted>
  <last_update_submitted>February 25, 2021</last_update_submitted>
  <last_update_submitted_qc>February 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>aprepitant therapy</keyword>
  <keyword>fosaprepitant therapy</keyword>
  <keyword>5HT3-receptor antagonist</keyword>
  <keyword>dexamethasone</keyword>
  <keyword>colorectal cancer</keyword>
  <keyword>FOLFOX</keyword>
  <keyword>XELOX</keyword>
  <keyword>SOX</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aprepitant</mesh_term>
    <mesh_term>Fosaprepitant</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

